Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Cortes

Showing results (421-430 of 584) with videos related to

Pageof 59
Sort By:
British Journal of Haematology|May 23, 2013
Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 studyNeil P Shah, Moshe Talpaz, Michael W N Deininger, et al.
American Journal of Hematology|July 23, 2020
Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patientsGautam Borthakur, Zhihong Zeng, Jorge E Cortes, et al.
Blood|November 11, 2010
Targeting neuropilin-1 in human leukemia and lymphomaKatja Karjalainen, Diana E Jaalouk, Carlos E Bueso-Ramos, et al.
Journal of Cancer Research and Clinical Oncology|April 17, 2019
Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemiaJorge E Cortes, Carlo Gambacorti-Passerini, Michael W Deininger, et al.
The Lancet. Haematology|December 22, 2015
Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics studyGiovanni Martinelli, Vivian G Oehler, Cristina Papayannidis, et al.
Blood|August 15, 2002
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemiaHagop M Kantarjian, Susan O'Brien, Jorge E Cortes, et al.
Haematologica|May 19, 2018
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II studyCarlo Gambacorti-Passerini, Jorge E Cortes, Jeff H Lipton, et al.
Leukemia & Lymphoma|July 28, 2010
Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapyQaiser Bashir, Marcos J De Lima, John D McMannis, et al.
Haematologica|October 22, 2013
Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoringRajyalakshmi Luthra, Keyur P Patel, Neelima G Reddy, et al.
Leukemia|May 24, 2003
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapyA-M Tsimberidou, H M Kantarjian, E Estey, et al.
Pageof 59

Showing results (421-430 of 584) with videos related to

Sort By:
Pageof 59
British Journal of Haematology|May 23, 2013
Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 studyNeil P Shah, Moshe Talpaz, Michael W N Deininger, et al.
American Journal of Hematology|July 23, 2020
Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patientsGautam Borthakur, Zhihong Zeng, Jorge E Cortes, et al.
Blood|November 11, 2010
Targeting neuropilin-1 in human leukemia and lymphomaKatja Karjalainen, Diana E Jaalouk, Carlos E Bueso-Ramos, et al.
Journal of Cancer Research and Clinical Oncology|April 17, 2019
Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemiaJorge E Cortes, Carlo Gambacorti-Passerini, Michael W Deininger, et al.
The Lancet. Haematology|December 22, 2015
Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics studyGiovanni Martinelli, Vivian G Oehler, Cristina Papayannidis, et al.
Blood|August 15, 2002
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemiaHagop M Kantarjian, Susan O'Brien, Jorge E Cortes, et al.
Haematologica|May 19, 2018
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II studyCarlo Gambacorti-Passerini, Jorge E Cortes, Jeff H Lipton, et al.
Leukemia & Lymphoma|July 28, 2010
Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapyQaiser Bashir, Marcos J De Lima, John D McMannis, et al.
Haematologica|October 22, 2013
Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoringRajyalakshmi Luthra, Keyur P Patel, Neelima G Reddy, et al.
Leukemia|May 24, 2003
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapyA-M Tsimberidou, H M Kantarjian, E Estey, et al.
Pageof 59